TABLE 2.
Pneumonia characteristics of randomized patients at study entrya
| Characteristic | No. (%) of patients
|
|
|---|---|---|
| Cefepime (n = 59) | Ceftriaxone (n = 56) | |
| Diagnosis | ||
| Lobar pneumonia | 43 (72.9) | 44 (78.6) |
| Bronchopneumonia | 15 (25.4) | 12 (21.4) |
| Interstitial infiltrate | 1 (1.7) | 0 |
| Siteb | ||
| Right lung | 47 (79.7) | 34 (60.7) |
| Left lung | 12 (20.3) | 22 (39.3) |
| Severityb | ||
| Mild | 11 (18.6) | 6 (10.7) |
| Moderate | 48 (81.4) | 46 (82.1) |
| Severe | 0 | 4 (7.1) |
| Chronicity | ||
| Acute | 58 (98.3) | 56 (100) |
| Other | 1 (1.7) | 0 |
| Classification | ||
| Single lung lobe | 40 (67.8) | 38 (67.9) |
| Multiple lung lobe | 6 (10.2) | 5 (8.9) |
| Both lungs | 13 (22.0) | 13 (23.2) |
a
The mean number of days of infection before study entry were 4.5 and 5.7 for the cefepime and ceftriaxone groups, respectively.
b
P < 0.05.